|  |  |  |
| --- | --- | --- |
| eLIBRARY ID: [41152494](https://elibrary.ru/item.asp?id=41152494) |  |  |

|  |  |
| --- | --- |
|  | **MODERN PRECONDITIONS FOR THE PREVENTION AND TREATMENT OF REFRACTORY FORMS OF MULTIPLE MIELOMA DEVELOPMENT** |

|  |  |
| --- | --- |
|  | **KOSTYUKOVA N.**1, **ROSSOKHA Z.**2, **GOROVENKO N.**3, **VYDYBORETS S.**31 Kyiv Centre of Bone Marrow Transplantology, Kyiv, Ukraine2 Reference-center for molecular diagnostic of Public Health Ministry of Ukraine, Kyiv, Ukraine3 [Shupyk National Medical Academy Postgraduate Education](https://elibrary.ru/org_items.asp?orgsid=13882" \o "Национальная медицинская академия последипломного образования им. П.Л. Шупика), Kyiv, Ukraine |

|  |
| --- |
| Тип: статья в журнале - научная статья Язык: английский |
|  |
| Том: 5Номер: [3](https://elibrary.ru/contents.asp?id=41152490&selid=41152494) Год: 2019 Страницы: 281-289 Поступила в редакцию: 13.09.2019 |
|  |
|      УДК: 616-006.448-031.81-085.015.5/.8-092:575:577.23 |

|  |
| --- |
| ЖУРНАЛ: |
|   | [ГЕМАТОЛОГИЯ. ТРАНСФУЗИОЛОГИЯ. ВОСТОЧНАЯ ЕВРОПА](https://elibrary.ru/contents.asp?id=41152490)Издательство: [Издательское частное унитарное предприятие "Профессиональные издания"](https://elibrary.ru/publisher_titles.asp?publishid=8974) (Минск)ISSN: 2411-8966eISSN: 2414-3693 |

|  |
| --- |
| КЛЮЧЕВЫЕ СЛОВА: |
|   | [MULTIPLE MYELOMA](https://elibrary.ru/keyword_items.asp?id=815), [REFRACTORY FORM](https://elibrary.ru/keyword_items.asp?id=7070670), [GENE POLYMORPHISM](https://elibrary.ru/keyword_items.asp?id=17595), [CALCIUM](https://elibrary.ru/keyword_items.asp?id=4105), [ALPHA-2-GLOBULIN](https://elibrary.ru/keyword_items.asp?id=17673964), [МНОЖЕСТВЕННАЯ МИЕЛОМА](https://elibrary.ru/keyword_items.asp?id=2501521), [РЕФРАКТЕРНЫЕ ФОРМЫ](https://elibrary.ru/keyword_items.asp?id=17673965), [ПОЛИМОРФИЗМ ГЕНОВ](https://elibrary.ru/keyword_items.asp?id=2334284), [КАЛЬЦИЙ](https://elibrary.ru/keyword_items.asp?id=2330496), [АЛЬФА-2-ГЛОБУЛИН](https://elibrary.ru/keyword_items.asp?id=17673966) |

|  |
| --- |
| АННОТАЦИЯ: |
|   | Treatment of multiple myeloma has progressed significantly over the past years after the introduction of immunomodulation drugs and proteasome inhibitors. The median of overall survival improved. All patients with multiple myeloma have relapses during a different time interval. The duration of the achieved remission in patients with a relapse of multiple myeloma becomes shorter with each subsequent case. The choice of regimen for relapse of multiple myeloma is very complex. It depends on a number of factors, including the previous induction regimen, the number of lines of the previous therapy, and the degree of aggression of relapse. The article is devoted to peculiarities of drug resistance formation in the first line therapy in patients with multiple myeloma by assessing of genetic markers (deletion variants of GSTT1, GSTM1 genes, GSTP1 (А313G), MDR1 (C3435T)) and clinical-hematological, laboratory characteristics. Purpose. Devoted to peculiarities of drug resistance formation in the first line therapy in patients with multiple myeloma by assessing of genetic markers (deletion variants of GSTT1, GSTM1 genes, GSTP1 (А313G), MDR1 (C3435T)) and clinical-hematological, laboratory characteristics for predicting the effectiveness of treatment...▼Показать полностью |